Contribution of angiotensin II to alcohol-induced pancreatic fibrosis in rats

被引:11
作者
Uesugi, T
Froh, M
Gäbele, E
Isayama, F
Bradford, BU
Ikai, I
Yamaoka, Y
Arteel, GE
机构
[1] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA
[2] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA
[3] Univ N Carolina, Dept Pharmacol, Hepatobiol & Toxicol Lab, Chapel Hill, NC 27599 USA
[4] Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Kyoto, Japan
关键词
D O I
10.1124/jpet.104.071324
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The mechanisms by which alcohol causes pancreatic fibrosis remain unknown. Recent studies have demonstrated that angiotensin II contributes to the development of fibrosis in liver, kidney, and heart injury. Here, the effects of angiotensin-converting enzyme inhibitor ( captopril) and angiotensin II receptor antagonist (losartan) on alcohol-induced pancreatic fibrosis were examined in an intragastric ethanol-feeding model. Male rats were fed a high-fat liquid diet with either ethanol ( 16 - 20 g/kg/day) or isocaloric maltose-dextrin ( control) for 4 weeks. Subgroups daily received captopril (60 mg/kg/day), losartan ( 3 mg/kg/day), or no additional agent included in liquid diets. Mean urine alcohol concentrations in all groups fed ethanol were more than 270 mg/dl and not significantly different. Dietary alcohol caused diffuse gland atrophy and interlobular and intralobular fibrosis with mild structural distortion in the pancreas, an effect that was blunted by captopril or losartan treatment. Alcohol also increased the number of alpha-smooth muscle actin-positive cells and transforming growth factor-beta mRNA expression in the pancreas. These increases were blunted significantly by captopril or losartan treatment. These data suggest that angiotensin II contributes to the development of chronic alcohol-induced pancreatic fibrosis through its stimulation of transforming growth factor-beta expression.
引用
收藏
页码:921 / 928
页数:8
相关论文
共 47 条
  • [1] The natural history of pain in alcoholic chronic pancreatitis
    Ammann, RW
    Muellhaupt, B
    [J]. GASTROENTEROLOGY, 1999, 116 (05) : 1132 - 1140
  • [2] Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS30
  • [3] Identification, culture, and characterization of pancreatic stellate cells in rats and humans
    Bachem, MG
    Schneider, E
    Gross, H
    Weidenbach, H
    Schmid, RM
    Menke, A
    Siech, M
    Beger, H
    Grünert, A
    Adler, G
    [J]. GASTROENTEROLOGY, 1998, 115 (02) : 421 - 432
  • [4] BADGER TM, 1993, J PHARMACOL EXP THER, V264, P938
  • [5] Bergmeyer, 1983, METHODS ENZYMATIC AN, DOI DOI 10.1111/J.1432-1033.1989.TB14834.X
  • [6] Chronic liver injury, TGF-β, and cancer
    Bissell, DM
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2001, 33 (04) : 179 - 190
  • [7] The renin-angiotensin-aidosterone system and fibrinolysis in progressive renal disease
    Brown, NJ
    Vaughan, DE
    Fogo, AB
    [J]. SEMINARS IN NEPHROLOGY, 2002, 22 (05) : 399 - 406
  • [8] EFFECT OF ALCOHOL AND SMOKING ON PANCREATIC LITHOGENESIS IN THE COURSE OF CHRONIC-PANCREATITIS
    CAVALLINI, G
    TALAMINI, G
    VAONA, B
    BOVO, P
    FILIPPINI, M
    RIGO, L
    ANGELINI, G
    VANTINI, I
    RIELA, A
    FRULLONI, L
    DIFRANCESCO, V
    BRUNORI, MP
    BASSI, C
    PEDERZOLI, P
    [J]. PANCREAS, 1994, 9 (01) : 42 - 46
  • [9] FACTORS INFLUENCING MYOFIBROBLAST DIFFERENTIATION DURING WOUND-HEALING AND FIBROSIS
    DESMOULIERE, A
    [J]. CELL BIOLOGY INTERNATIONAL, 1995, 19 (05) : 471 - 476
  • [10] DURKEC JP, 1978, DIGESTION, V18, P337